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noside 3g/m2 x 6 and TBI 1200-1400 cGy. In addition, AD
recipients received either ex vivo partial T-cell depletion or
Campath to achieve in vivo T-cell depletion in an effort to
reduce the risk of GVHD. Five AD patients died; 4 patients in
chronic phase and 1 patient in accelerated phase prior to trans-
plant. One patient died from recurrent disease and the other 4
from complications of therapy: 1 engraftment failure; 1 poor
engraftment and fungal disease; 1 cryptosporidium parasitemia;
and 1 pulmonary hemorrhage with viral infections. After trans-
plantation, 30% in each group (MSD and AD) required addi-
tional Gleevec or donor leukocyte infusions for BCR/ABL pos-
itivity. The Kaplan-Meier estimate of disease-free survival at 2
years was 78% for the entire cohort: 100% for the MSD group
and 56% for the AD group. Only 1 patient (AD recipient)
developed grade 3-4 acute GVHD and only 1 patient (AD
recipient) developed extensive, chronic GVHD. We conclude
that stem cell transplantation provides effective leukemia con-
trol and potential cure even for patients with advanced disease
who lack an MSD. Regimen-related mortality remains an im-
pediment to improved outcome for pediatric CML patients
receiving stem cells from unrelated or mismatched donors.
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ASSESSMENT OF ADENOVIRUS SUBGENERA PREVALENCE BY REAL-
TIME PCR IN IMMUNOCOMPROMISED PATIENTS
Duncan, K.1, Reddy, S.1, Vats, A.2, Kleiboeker, S.1 1ViraCor Labora-
tories, Lee’s Summit, MO; 2Children’s Hospital of Pittsburgh, Division
of Pediatric Nephrology, Pittsburgh, PA.
Background: Adenoviruses (Adv) are double-stranded DNA
viruses that can be classiﬁed by serotypes (1-51), which are
grouped into six subgenera (A-F). Within the different subgen-
era, viral characteristics vary in terms of host range, disease
type, and genetic composition. Real-time PCR has proven to be
a rapid, sensitive, and speciﬁc way to analyze the variable re-
gions of the Adv genome for subgenera determination. Using
this methodology, we determined the prevalence of Adv sub-
genera in a variety of Adv-positive clinical specimens collected
from immunocompromised patients.
Methods: Initially we utilized real time PCR TaqMan®
chemistry to quantify AdV DNA in clinical specimens using a
single pair of primers and a minor groove-binding probe (MGB)
designed to detect and quantitate all 51 Adv serotypes. From
specimens that were determined to be Adv-positive with this
assay, we randomly selected twenty-eight plasma, twenty-one
urine, and three fecal/rectal samples for Adv subgenera classi-
ﬁcation. Each specimen was analyzed by six individual Taq-
Man® assays (Watzinger et al., J. Clin. Microbiol 42:5189),
each designed to speciﬁcally detect all known serotypes within
each of the six subgenera.
Results: Plasma specimens tested with the pan-AdV assay had
viral loads ranging from 7.34101 – 5.73106 copies/ml. Urine
specimens had viral loads ranging from 1.24102 – 1.57107
copies/ml, and fecal/rectal samples had viral loads ranging from
9.04103 – 1.02.x107 0107 copies/ml. Subgenera determina-
tion for plasma demonstrated that 21% (6 samples) were Sub-
genus B, and 79% (22 samples) were Subgenus C. Results from
urine demonstrated that 81% (17 samples) were Subgenus B,
14% (3 samples) were Subgenus C, and 5% (1 sample) was
Subgenus D. Of the three fecal/rectal samples two were Subge-
nus D and one was Subgenus F. Using Fisher’s Exact Test, the
subgenera distribution among plasma and urine was determined
to be signiﬁcantly different (P0.0001; odds ratio20.78, 95%
CI: 4.526 to 95.38).
Conclusion: Results of this study demonstrate that the prev-
alence of AdV subgenera differ signiﬁcantly among specimen
types collected from immunocompromised patients. The pre-
dominant subgenus identiﬁed in urine was B while the predom-
inant subgenus identiﬁed in plasma was C. These results support
previous ﬁndings for prevalence in plasma and urine. Real-time
PCR technology provides an efﬁcient means to accurately diag-
nose Adenovirus infections and identiﬁcation of AdV subgenera.
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SUCCESSFUL HSCT AFTER MULTIVISCERAL TRANSPLANTATION
Kleiner, G.I.1, Gonzalez-Brito, M.1, Weppler, D.2, White, E.1,
Simon, N.3, David, A.2, Selvaggi, G.2, Kato, T.2, Shariatmadar, S.4,
Tzakis, A.2 1Department of Pediatrics, University of Miami, Miami,
FL; 2Division of Liver-GI Transplantation, University of Miami, Mi-
ami, FL; 3Jackson Memorial Hospital, Miami, FL; 4Department of
Pathology, University of Miami, Miami, FL.
Severe aplastic anemia following liver transplantation is a rare
phenomenon. We report the case of an eight year old girl who
developed SAA following multivisceral transplantation. The pa-
tient was diagnosed with intestinal pseudo obstruction and un-
derwent modiﬁed multivisceral transplant (stomach, pancreas,
spleen, small and large intestine) in December 2005. Post op-
erative course was uncomplicated but the patient developed SAA
six months later. There was no response to growth factors or
increased immunosuppression. The patient was housed in the
Pediatric ICU. Her brother was found to be HLA identical and
the patient underwent conditioning with Fludaribine 25mg/
m25, Cyclosphosphamide 50mg/kg x4, and ATG 30mg/kg x3.
She received 1.33  10e8 mnc/kg bone marrow. The patient
tolerated chemotherapy well. Post transplant course was com-
plicated by VRE treated with parenteral antibiotics and granu-
locyte transfusion support. The patient engrafted on day16.
FISH XY revealed 100% donor. We conclude that this reduced
intensity regimen may be effective in SAA cases following solid
organ transplantation.
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CORRELATION BETWEEN INFUSED MONONUCLEAR CELLS (MNC) AND
TRANSPLANT OUTCOME IN PEDIATRIC CORD BLOOD TRANSPLANTA-
TION (CBT). A STUDY OF 92 SINGLE CBT DONE AT CHILDREN’S
MEMORIAL HOSPITAL, CHICAGO, IL
Merchant, M.1, Olszewski, M.1, Huang, W.1, Duerst, R.1,2,
Jacobsohn, D.1,2, Kletzel, M.1,2 1Children’s Memorial Hospital, Chicago,
IL; 2Northwestern University Feinberg School of Medicine, Chicago, IL.
Objective:
To evaluate if there is a correlation between infused MNC cell
dose and transplant outcome in pediatric CBT.
Method:
Between January 1995 and February 2006, 125 CBT were carried
out at Children’s Memorial Hospital. 15 patients already had a
previous transplant and 18 patients required a subsequent trans-
plant after the initial CBT failed (primary or secondary graft failure
or relapse). Remaining 92 patients (43 female, 49 male) who un-
derwent a single CBT were evaluated in this study. 26 patients had
non-malignant conditions (SCID 7, HPCS 5, Wiskott-Aldrich
syndrome 3, 2 each of Aplastic anemia, Hurler’s syndrome and
Osteopetrosis, others 5) and 66 had malignancy (ALL 33, AML 21,
MDS 5, 2 each of Non-Hodgkin’s lymphoma and JMML, others
3). Disease status for malignancy at time of CBT was PR 7, CR1
24, CR2 28, CR 3/3 7. 69 patients received myeloablative con-
ditioning regimen (fTBI, VP-Cy, or Thiotepa. 4 patients received
Busulphan in place fTBI); 23 patients had reduced intensity con-
ditioning (Busulphan, Fludarabine, ATG). The median age at
transplant was 34.5 months (range 1 to 200), with median HLA
match of 4:6; ratio of cord sex was 53 female to 39 male. The
median MNC cell dose infused was 0.57  108/kg (range 0.08-
2.83). See table.
Results/Outcome:
Overall, 63 (68.5%) patients showed ANC engraftment (500
cells/	L), 58 (63.0%) showed PLT engraftment (20,000 cells/
	L) in a median of 24 (range 15- 60) and 44 (range 14- 105) days
respectively. 22 patients (23.9%) died within day 100 of CBT
from transplant related mortality. 13 patients (14.1%) had a re-
lapse. Overall 57 patients (62%) are event free at the present time
with an overall survival (OS) of 706 days.
Conclusions:
1. As the MNC cell dose increases, days required to achieve
engraftment (both ANC and PLT) decrease, showing these out-
come parameters are cell dose dependent.
2. Group 1 received the lowest cell dose (0.08- 0.29  108/kg)
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and has poor transplant outcome with a high TRM, a lower EFS
and a lower OS.
3. Group 2 (0.30- 0.85  108/kg) had the best overall engraft-
ment (both ANC and PLT) of close to 80%. TRM was lowest in
this group at 13% but the rate of relapse was higher than the other
groups.
4. Group 3 (0.86- 2.83  108/kg) received higher than the
median MNC cell dose. Compared to Group 2 though this group
shows a lower engraftment it shows comparable EFS. This group
shows that a higher cell dose results in higher TRM (8 of 9
patients) and fewer relapse (4%).
Transplant Outcome
MNC dose group
(x108/kg
Overall
(0.08- 2.83)
(1)
<0.29
(2)
0.30- 0.85
(3)
> 0.86
n 92 19 46 27
ANC engraftment 63; 68.5% 10; 52.6% 38; 79.2% 15; 55.6%
PLT engraftment 58; 63% 10; 52.6% 36; 78.3% 12; 44.4%
Days to ANC 24 36 26 18
Days to PLT 44 56 46 34
TRM 22; 23.9% 8; 42% 6; 13% 8; 29.6%
Relapse 13; 14.1% 3; 15.8% 9; 19.6% 1; 3.7%
EFS 57; 62% 8; 34.8% 31; 67.4% 18; 66.7%
OS (days) 706 326 1396 603
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HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR HEMATOLOGI-
CAL DISEASES AT YEDITEPE UNIVERSITY HOSPITAL
Yirmibescik, S.1, Senkal, V.1, Kalayci, G.1, Aktas, S.1, Aydin, D.1,
Sonmezoglu, M.1, Kocagoz, S.1, Oyan, B.1, Koc, Y.1 1Stem Cell Trans-
plant Unit, Yeditepe University Hospital, Istanbul, Turkey.
Stem cell transplantation(SCT) is an effective treatment modality
in hematological malignancies. SCT Unit at Yeditepe University
Hospital(CIC-919) was activated in October 2005 and accredited
for unrelated SCT by EBMT in April 2006. Until September 2006,
13 autologous and 17 allogeneic (4 unrelated) SCT have been
performed. Diagnosis of patients who underwent auto-SCT con-
sisted of HL(n6), NHL(n4) and myeloma (MM, n3). Patients
undergoing allo-SCT had HL(n2), NHL(n2), MM(n3),
CML(n3), CML-BT(n3), AML(n2), ALL(n1), and Thalas-
semia(n1). Median age was 38,5 (20-65) years and mean time
from diagnosis to transplant was 2,3 years. Patients received a
mean number of 8 (2-18) salvage regimens prior to transplantation.
All patients engrafted and median engraftment period was 11
(8-14) days. Transplantation related mortality(TRM) was not ob-
served during the ﬁrst 100 days and follow-up. Median follow-up
period was 5,4 (1-10,5) months. During follow-up, 5 patients
(16%) relapsed and 2 patients died (6%). Of 28 (94%) surviving
patients, 24 (80%) are in CR. All patients (100%) were alive
following auto-SCT at day 100, only one patient with myeloma
died due to relapse at 9 months. In the allo-SCT group, 16 (94%)
of patients were alive at day 100, only one patient died due to
relapse of CML-BT. Post-transplant complications were CMV
viremia(n9), CMV colitis(n3), sinusoidal occlusion syn-
drome(n1), BK viremia and hemorrhagic cystitis(n2), renal
failure(n1). Reversible blindness due to hypophyseal tumor apo-
plexy in a patient at day 11 was successfully corrected by neuro-
surgery. Grade II- III acute GVHD was observed in 8 pa-
tients(47%). All patients with acute GVHD were successfully
treated without mortality. A patient with refractory ALL associated
with CNS and eye involvement achieved complete remission fol-
lowing allo-SCT combined with modulated radiotherapy (IMRT).
All 4 patients (100%) who underwent unrelated-SCT following
autologous transplantation complicated with relapsed-refractory
disease are alive and 3 were in CR at day 100 (2 HL,1 NHL). Of
7 patients undergoing allo-SCT as a second transplant, 6 (85%) are
alive; in this group, only one patient with MM (15%) died due to
relapse. The high survival rate (94%) achieved following autolo-
gous and/or allogeneic SCT including unrelated transplants, low
TRM (0%) and the high remission rate (80%) may be related to
team approach, 24-hour patient follow-up, and effective manage-
ment of acute GVHD.
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VALIDATION OF THE HEMATOPOIETIC CELL TRANSPLANTATION-CO-
MORBIDITY INDEX (HCT-CI) FOR NON-RELAPSE MORTALITY (NRM)
AND SURVIVAL AFTER MATCHED UNRELATED DONOR SCT
Kovacsovics, T.1,2, Hayes-Lattin, B.1,2, Riegert, K.1, Subbiah, N.1,
Curtin, P.T.1,2, Leis, J.F.1,2, Mauro, M.M.1,2, Epner, E.E.1,2,
Fleming, W.H.1,2, Meyers, G.M.1,2, Deininger, M.W.1,2, Dunn, A.1,
Maziarz, R.T.1,2 1Center for Hematological Malignancies, OHSU,
Portland, OR; 2Oregon Cancer Institute, Portland, OR.
Background: The HCT-CI is a recently developed comorbidity
score which has been adapted to hematopoietic stem cell trans-
plantation, with higher scores associated to worse outcomes (Blood
2005;106:2912) . We determined the HCT-CI score in a cohort of
patients who underwent conventional MUD transplantation in a
single arm, single institution trial assessing efﬁcacy of a 3-drug
combination of cyclosporine, methotrexate and prednisone for
GVHD prophylaxis from 1996-2005.
Methods: The analysis included all patients undergoing MUD
transplant who received GVHD prophylaxis with cyclosporine 2
mg/kg iv BID from day -2, methotrexate 15 mg/m2 iv on day 1
and 10 mg/m2 iv on days3 and6, and methylprednisolone 0.25
mg/kg iv BID beginning on day 7 and tapering at day 28.
Patients were stratiﬁed by disease risk per CIBMTR classiﬁcation.
The comorbidities were obtained by retrospective chart review and
scored according to the HCT-CI score.
Results: 133 patients received the 3 drug-regimen, including 26
% with low-, 36 % with intermediate- and 38 % with high-risk
disease. Diagnoses included acute leukemia in 50%, MDS in 9.8%,
CML in 16.5%, lymphoma in 18.1%, multiple myeloma in 3.0%.
52 % were older than 40. Source of stem cells was PBSC in 47.4%,
marrow in 51.9%. and both in 0.8%. Among the 133 patients,
22%, 31% and 47% had HCT-CI scores of 0 vs 1-2 vs 3,
respectively. Overall NRM was 26.3% and 36.8%, at 3 months and
1 year, respectively. Three and 12 month NRM was 13.3%, 14.6
and 40.3% and 30%, 22% and 50% among patients with scores of
of 0 vs 1-2 vs 3, respectively. HR rates for 3 month NRM were
1.10 and 3.7 for HCT-CI scores 1-2 and 3. Kaplan-Meier as-
sessment showed 42.1% 5 year OS for the whole cohort. OS of
60%, 48.% and 28.1% were observed in patients with scores of of
0 vs 1-2 vs 3, respectively (p  0.05). No statistically signiﬁcant
differences in OS were observed between low-, intermediate- and
high-risk CIBMTR disease groups.
Conclusion: HCT-CI was a powerful predictor of 3 and 12
month NRM, as well as of 5 year OS in this cohort of MUD
patients. It will be useful for patient stratiﬁcation in clinical trials
and for treatment allocation.
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SYNGENEIC STEM CELL TRANSPLANTATION FOR APLASTIC ANEMIA IN
AN HIV PATIENT
Longoni, H.O.1, Binaghi, M.A.1, Kohan, A.I.1, Lasala, M.B.1,
Banchieri, A.V.1, Minissale, C.J.1, Plana, J.L.1, Velicche, A.F.1,
Christin, M.P.1, Corach, D.2, Maissonnave, V.1, Calahonra, R.1 1Hos-
pital de Clinicas Jose´ de San Martı´n; University of Buenos Aires, Buenos
Aires, Argentina; 2Facultad de Farmacia y Bioquı´mica; University of
Buenos Aires, Buenos Aires, Argentina.
Allogeneic hematopoietic stem cell transplantation from HLA
identical siblings is an effective treatment for aplastic anemia in
young patients. Heavily transfused patiens have shown an increased
risk of graft rejection requiring a more intensive immunosuppres-
sive conditioning. Usually a combination of cyclophosphamide
(Cy) with total body irradiation (TBI) or more recently with
antithimocyte globuline (ATG) is used.
We report a 32 year old patient with haemorragic manifestations,
haemodynamic instability and pancytopenia, admitted to the Hos-
pital in February 2005. Bone marrow biopsy performed, conﬁrmed
the diagnosis of aplastic anemia, Human Immunodeﬁciency Virus
(HIV) seropositivity was assessed by 2 different methods. No other
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